Precision Medical Ventures, Inc. Dba Revealdx

Seattle, WA, United States All United States companies → — Founded 2021

Imaging AI Specialist Specialty-Focused AI

Oncology Pulmonology Radiology

Series B — $8.23M

Claim this company

Products

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx

Oncology AI

RevealAI-Lung is an AI lung nodule characterization tool designed to support early lung cancer assessment by providing a Malignancy Similarity Index (mSI) score from CT scans.

Subscription

See all 1 product →

About Precision Medical Ventures, Inc. Dba Revealdx

Precision Medical Ventures, Inc. Dba Revealdx (RevealDx) is a Seattle-based healthcare AI company focused on dramatically improving lung cancer outcomes through non-invasive diagnosis. They develop advanced, radiomics and AI-enabled, lung cancer decision support software. Their flagship product, RevealAI-Lung, is a Computer-Assisted Diagnostic (CADx) software that analyzes patient lung computed tomography (CT) images to provide information about lung nodules to radiologists.

RevealAI-Lung characterizes incidental lung nodules by generating a Malignancy Similarity Index (mSI), a score that assists radiologists in making more informed follow-up recommendations for cancer diagnosis. The software has been extensively validated in clinical trials, including studies with over 1,500 patients, demonstrating improved diagnostic precision and the ability to reduce false positives. It integrates directly into Picture Archiving and Communication Systems (PACS) to minimize disruption to radiology workflows and is reimbursable by U.S. Medicare under CPT codes 0721T and 0722T. RevealDx’s technology has received FDA clearance in the U.S., MDR certification in Europe, and TGA approval in Australia.

Focus Areas

AI characterization of lung nodules radiomics lung cancer decision support software medical imaging AI precision medicine

Business Intelligence

Key Investors	Westway Capital, 4DMedical, A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, Life Science Angels
Partnerships	4DMedical, Azra AI, TriHealth, Sirona, Riverain, Fuji PACS, contextflow
Acquisitions	Mindshare Medical (acquired by Precision Medical Ventures in March 2021)
Technology	AI-enabled lung cancer decision support software, radiomics, machine learning, direct PACS integration, cloud-native
FDA Clearances	1 cleared products (estimated)

What Physicians Need to Know

Specialization

AI-powered lung cancer decision support software, focusing on the characterization of lung nodules using radiomics and machine learning.

Key Differentiator - Malignancy Similarity Index (mSI)

RevealDx's core technology, RevealAI-Lung, generates a Malignancy Similarity Index (mSI) score from CT scans to assess the risk of malignancy in lung nodules. This score aids radiologists in making more informed follow-up recommendations.

Key Differentiator - Non-Invasive Diagnosis

The company's mission is to dramatically improve lung cancer outcomes through non-invasive diagnosis, which is particularly important given the high morbidity and mortality rates associated with lung biopsies and surgeries.

Key Differentiator - Improved Diagnostic Accuracy

Clinical studies have shown that RevealAI-Lung significantly improves radiologists' accuracy in diagnosing pulmonary nodules, with one study demonstrating an average improvement of 18 points (from 0.54 to 0.72 AUC).

Key Differentiator - Reduced Unnecessary Procedures & Early Diagnosis

The technology aims to reduce unnecessary procedures and accelerate lung cancer diagnosis. It has the potential to identify up to 45% of malignant nodules when they first appear, reducing delayed cancer diagnoses.

Technology Stack - AI and Machine Learning

RevealDx leverages advanced radiomics and AI, specifically machine learning techniques, to analyze chest CT scans and characterize lung nodules.

Technology Stack - Proprietary Analytics

The software employs proprietary analytics, including a patented approach that provides improved stability across image types and transparency of predictions. It extracts local predictive value from 3D analysis of lesions and enhances results with broader lung and chest analysis.

Regulatory Clearances

RevealAI-Lung has received FDA clearance in the US, MDR Certification in Europe, and TGA approval in Australia.

Reimbursement

In the US, RevealAI-Lung is reimbursable under Medicare Outpatient Prospective Payment System (OPPS) using Category III CPT codes 0721T and 0722T, at a rate of approximately $650.

Clinical Validation

The software has been extensively validated in clinical trials and years of research, including validation on over 1,500 patients from various cohorts.

Physician Tip

For physicians, RevealDx's RevealAI-Lung offers a powerful tool to enhance lung nodule assessment. The Malignancy Similarity Index (mSI) provides objective, AI-driven insights to aid in distinguishing benign from malignant nodules, potentially leading to earlier cancer diagnoses and reducing unnecessary invasive procedures. The software's direct integration into PACS systems streamlines workflow, allowing for single-click operation and rapid results. This augmentative technology uncovers radiomic biomarkers invisible to the human eye, adding significant value to radiologists' decision-making process and ultimately improving patient outcomes and potentially reducing healthcare costs.

RevealDx's RevealAI-Lung is designed for direct integration into Picture Archiving and Communication Systems (PACS), aiming to minimize disruption to radiologists' existing workflows. They have announced integrations with Riverain, Fujifilm PACS, and Sirona Medical's cloud-native radiology workflow platform. Additionally, a partnership with 4DMedical will embed RevealAI-Lung into their contextflow chest CT platform, combining AI risk scoring with functional lung physiology.

At a glance

Founded 2021

HQ Seattle, WA, United States · United States

Team size 13-14

CEO Chris Wood

Funding Series B — $8.23M

FDA clearances 1 (estimated)

Products 1

Products by Precision Medical Ventures, Inc. Dba Revealdx

1 product in the directory

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx

Oncology AI

RevealAI-Lung is an AI lung nodule characterization tool designed to support early lung cancer assessment by providing a Malignancy Similarity Index (mSI) score from CT scans.

Subscription

Reviews & Opinions

No web reviews on file yet for Precision Medical Ventures, Inc. Dba Revealdx. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Precision Medical Ventures, Inc. Dba Revealdx.

Loading videos...

Videos load interactively. If none appear, search YouTube for Precision Medical Ventures, Inc. Dba Revealdx →

View all on YouTube

Press & Coverage

FDA

510(k) Premarket Notification - K251769

Precision Medical Ventures, Inc. Dba Revealdx received 510(k) clearance from the FDA for its RevealAI-Lung device, a radiological computer-assisted diagnostic software for lesions suspicious of cancer. The device is intended to aid in the characterization of incidentally-detected lung nodules on CT scans.

2026-01

OpenRegulatory

RevealAI-Lung | Precision Medical Ventures, Inc. Dba Revealdx

This entry details the FDA 510(k) clearance (K251769) for Precision Medical Ventures, Inc. Dba Revealdx's RevealAI-Lung, a device for radiological image analysis. The decision date for this clearance was January 30, 2026.

2026-01

Health AI Company Directory

Health AI Company Directory - Precision Medical Ventures, Inc. Dba Revealdx

RevealDx, established in 2021, develops AI-enabled lung cancer decision support software called RevealAI-Lung. This software characterizes incidental lung nodules using a proprietary Malignancy Similarity Index (mSI) and integrates with PACS systems to assist radiologists.

unknown

FDA

TPLC - Total Product Life Cycle - FDA

Precision Medical Ventures, Inc. Dba Revealdx is listed in the FDA's Total Product Life Cycle database, indicating their RevealAI-Lung device (K251769) has been deemed substantially equivalent to a predicate device.

2026-08

Frequently Asked Questions

What specific AI technologies does Revealdx utilize for lung nodule characterization and how do they improve diagnostic accuracy?

Revealdx leverages advanced AI, including deep learning and radiomics, to analyze medical images for lung nodule characterization. This technology extracts quantitative features from imaging data that are often imperceptible to the human eye, aiming to provide more objective and precise assessments of nodule malignancy risk, thereby enhancing diagnostic accuracy and potentially reducing unnecessary invasive procedures.

How does Revealdx's lung cancer decision support software integrate with existing PACS and EMR systems, and what is its impact on clinical workflow?

Revealdx's lung cancer decision support software is designed for seamless integration with existing PACS (Picture Archiving and Communication Systems) and EMR (Electronic Medical Record) systems through standard protocols like DICOM and HL7. This integration allows for automated data transfer and analysis, providing clinicians with timely, AI-powered insights directly within their established workflows, which can streamline decision-making and improve efficiency without significant disruption.

What evidence supports the clinical efficacy and cost-effectiveness of Revealdx's medical imaging AI solutions in a real-world precision medicine setting?

Revealdx is committed to demonstrating the clinical efficacy and cost-effectiveness of its AI solutions through rigorous validation studies and real-world data analysis. Our solutions aim to improve patient outcomes by enabling earlier and more accurate diagnoses, potentially reducing healthcare costs associated with delayed or incorrect diagnoses and unnecessary interventions.

What are Revealdx's pricing models for its AI software and what kind of technical support and training are provided to healthcare institutions?

Revealdx offers flexible pricing models tailored to the needs of different healthcare institutions, which can include subscription-based licensing or per-study fees. We provide comprehensive technical support, including dedicated account management, 24/7 technical assistance, and ongoing training programs for medical staff to ensure optimal utilization and integration of our AI solutions.

How does Revealdx ensure compliance with medical device regulations (e.g., FDA, CE Mark) and data privacy standards (e.g., HIPAA, GDPR) for its AI products?

Revealdx prioritizes regulatory compliance and data privacy, adhering to stringent standards such as FDA regulations, CE Mark requirements, HIPAA, and GDPR. Our products undergo rigorous testing and validation, and our data handling practices are designed to ensure the highest levels of security and patient confidentiality.

What is the long-term vision for Revealdx's product roadmap, including future developments in AI for other cancer types or medical conditions?

Revealdx's long-term vision extends beyond lung cancer to encompass AI-powered diagnostic and decision support solutions for a broader range of cancer types and medical conditions. Our product roadmap includes continuous innovation in AI algorithms, expansion into new imaging modalities, and the development of integrated platforms that support comprehensive precision medicine initiatives across various specialties.

What is the company's stability and what are Revealdx's strategic partnerships within the healthcare and technology sectors?

Revealdx is a stable and growing company with a strong foundation in medical AI innovation. We have established strategic partnerships with leading academic institutions, medical device manufacturers, and technology providers to further enhance our research and development capabilities, expand our market reach, and ensure the seamless integration of our solutions within the healthcare ecosystem.

Related Companies

Suggest an Edit →